Sign inJoin waitlistJoin the waitlist

Kari Wisinski

Medical Oncology · University of Wisconsin Medical Foundation

Credentials: · · ·

History

University of Wisconsin Hospitals and Clinics
2004–2006
Internal Medicine
University of Colorado School of Medicine
2001–2004
University of Wisconsin School of Medicine and Public Health
1997–2001

Research

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 914 citations
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 759 citations
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024 · 560 citations

Amye Tevaarwerk
20 papers
Mark Burkard
18 papers
Ruth O’Regan
15 papers
Doreen Agnese
9 papers
Marina Sharifi
7 papers · 3 as a resident
Matthew Goetz
7 papers
Rebecca Aft
7 papers
William Gradishar
7 papers
Anthony Elias
6 papers
Bethany Anderson
6 papers
CD
Chau Dang
6 papers
Erica Stringer-Reasor
6 papers

Grants

National Clinical Trials Network Research at the University of Wisconsin
National Cancer Institute · UG1
Contact PI · $3.1M · University of Wisconsin-Madison
2019–2032
UW Comprehensive Cancer Center Support
National Cancer Institute · P30
Project lead · $2M · University of Wisconsin-Madison
1997–2028

Clinical trials

Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer
Principal investigator · Not yet recruiting · Phase 2
University of Wisconsin, Madison
2026–2028
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
Principal investigator · Terminated · Phase 2
University of Wisconsin, Madison
2021–2023
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
Principal investigator · Recruiting · Early phase 1
University of Wisconsin, Madison
2020–2027
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Principal investigator · Active not recruiting · Phase 1, Phase 2
Kari Wisinski
2019–2024